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Abstract 
The Mantoux Tuberculin Skin Test (TST) is the standard method for detecting latent tuberculosis and has been provided by pharmacists 
since at least 2006. In the largest published study of pharmacy-based TST involving 578 patients, the most common reason for obtaining 
the test were employment or school requirements. Pharmacists have demonstrated high rates of follow-up for the reading of the test, 
reported to be 92.8% to 94.4%. The biggest barrier to pharmacy-based TST is that a prescription is required for the two tuberculosis 
(TB) purified protein derivative products available on the market in the United States. States have adopted three strategies to enable 
pharmacy-based TST prescribing: 1) collaborative practice agreements; 2) statewide protocols; and 3) independent prescribing. These 
three approaches are reviewed, with a focus on the New Mexico statewide protocol and the recent statutory authority in Idaho that 
grants pharmacists independent prescriptive authority for TST. States may consider pursuing more autonomous models of TST 
prescribing given the safety and track record of this service at pharmacies. 
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Background 
The Mantoux Tuberculin Skin Test (TST) has been the standard 
method for detecting latent tuberculosis since the 1930s.1 The 
TST involves three steps: 1) intradermal administration into 
the forearm; 2) reading of the test result 48 to 72 hours after 
administration; and 3) interpretation of the result by 
measuring the induration in millimeters and comparing that 
measurement to thresholds listed by the Centers for Disease 
Control and Prevention (CDC).2 In interpreting the result, the 
healthcare provider must first conduct a risk assessment that 
takes into account recent travel, country of childhood, and co-
morbid conditions that may increase the risk for tuberculosis. 
If a patient tests “positive” in the TST, they should be referred 
for a medical evaluation including follow-up diagnostics and 
consideration for treatment.3 
 
The TST has been provided by pharmacists since at least 2006.4 
In the first published study on the topic, 18 TSTs were 
administered by two pharmacists in a grocery store setting. 
Hecox noted that TSTs were “easily incorporated into 
workflow” and estimated that each test took roughly 10 
minutes.4 The types of patients who seek the TST at 
pharmacies tend to be low-risk for tuberculosis infection. In 
the largest published study of pharmacy-based TST involving 
578 patients, the most common reason for obtaining the test 
were employment or school requirements.5 Other studies 
have reported pharmacists screening pharmacy students prior 
to their experiential rotations; patients prior to starting  
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immunosuppressive biologic therapy; and patients beginning  
drug treatment programs.4,6-7 Pharmacists have demonstrated 
high rates of follow-up for the reading of the test, reported to 
be 92.8% to 94.4%.4-5 This is likely attributable to the 
convenience and accessibility of pharmacies, which are often 
open nights and weekends when many other health 
professional offices are closed. In addition, common venues 
for care, such as county health departments, may be                   
difficult to access for many patients and have limited                     
hours of operation that pose challenges for a test                              
that requires two trips within 72 hours. 
 
Some schools of pharmacy have started teaching TST as part 
of the Doctor of Pharmacy curriculum. The University of 
Washington taught second year professional pharmacy 
students, and found significant gains in comfort and 
willingness to perform TST following completion of the 
course.7 The CDC offers a free online video training on the 
Mantoux TST that may be leveraged by pharmacists and other 
healthcare professionals.8 Further, the Washington State 
Pharmacy Association offers a TST certificate training program 
for pharmacists, comprised of a 1.5 hour online module, and a 
practicum with a demonstration of technique and reading of 
the result on practice arms.9 
 
Despite the potential benefits of pharmacy-based TST, the 
biggest barrier to widespread adoption is that a prescription is 
required for the two tuberculosis (TB) purified protein 
derivative products available on the market in the United 
States (Table 1). As such, either pharmacists must receive a 
prescription for each TST, or there must be a mechanism in 
place for pharmacists to prescribe the products. Current state 
approaches to prescriptive authority have occurred across a 
continuum. This manuscript will describe different approaches 
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states have taken to pharmacy-based TST prescribing as a 
guide to other states considering this service. 
 
Pharmacist Prescriptive Authority for TST 
As described by Adams and Weaver, pharmacist prescriptive 
authority occurs along a continuum with the two primary 
categories being 1) collaborative prescribing; and 2) 
autonomous prescribing.10 We identified two states that allow 
autonomous models of pharmacists prescribing TST: Idaho 
(independent prescribing) and New Mexico (statewide 
protocol). Most remaining states allow TST under collaborative 
practice models of prescriptive authority in some form or 
fashion, though the feasibility varies by state. 
 
1) Collaborative Practice Authority 
Collaborative Practice Agreements (CPAs) form the basis of 
collaborative prescribing. CPAs are agreements between a 
prescriber and a pharmacist that allow the pharmacist to 
provide certain services that are outside his or her traditional 
legal scope of practice, but for which the pharmacist is 
educationally prepared and capable of performing.11 CPAs are 
voluntarily negotiated between the prescriber and the 
pharmacist. As such, CPAs serve as a framework to allow 
pharmacists to provide new services like TST.  
Not all collaborative practice laws are created equally, 
however. Adams and Weaver distinguished between “patient-
specific” and “population-specific” CPAs.10 In a patient-specific 
CPA, the patients who may receive service from the 
pharmacist are limited to those patients listed in the 
agreement, or limited to the patient panel of the collaborating 
prescriber. Thus a patient-specific CPA is not conducive to TST 
in an outpatient setting, as it is difficult to predict in advance 
which patients may benefit from a service. A patient-specific 
CPA may prove useful in some limited situations, such as in a 
clinic, or in a situation in which the known population of 
potential patients is well established (such as for a class of 
pharmacy students prior to experiential rotations). In addition, 
some patient-specific CPA laws restrict the initiation of new 
medications, and allow only modifying existing regiments. 
Such laws may prevent the initiation of a new TST. 
 
For a CPA to be practical for TST in outpatient settings, a 
population-specific CPA law is necessary. In a population-
specific CPA, inclusion and exclusion criteria are written by the 
collaborating professionals, but the service is not limited to 
individual patients of that prescriber. As of 2016, 17 states 
allowed population-specific CPAs, and thus may provide a 
framework to enable TST.10 
 
2) Statewide Protocol 
The New Mexico state legislature passed legislation in 2011 
authorizing the Board of Pharmacy to issue a statewide 
protocol outlining conditions under which pharmacists may 
prescribe and administer TST.5,12-13 Pharmacists must follow 
the Board’s protocol in order to lawfully prescribe TST in the 
state. The New Mexico protocol requires pharmacists to follow 
the CDC guidelines for skin testing. Further pharmacists must 
“take patient histories and consult with patients’ medical 
providers as appropriate.” With respect to the history, the 
following are required for the health screening: patient 
history, family history, current living environment, concurrent 
illness, allergies and hypersensitivities, and medication history. 
The New Mexico protocol details specific procedures for 
pharmacists to follow (e.g., inject 0.1 ml into the inner surface 
of the forearm) and reiterates clinical guidelines (e.g., read test 
between 48 and 72 hours). The protocol specifies 
recordkeeping requirements including the consent form, 
records of prescriber notification, billing, and prescription 
orders. All positive reports must be sent to the Department of 
Health and to the patient’s primary care provider. In addition, 
notification must be made to the patient’s primary care 
provider within 15 days of writing the TST prescription. 
 
3) Independent Prescribing 
The Idaho state legislature recently passed House Bill 3, which 
will allow unrestricted pharmacist prescribing of tuberculin 
purified protein derivative products when it takes effect on 
July 1, 2017.14 Thus, no CPA will be needed, and there is no 
statewide protocol that the Board of Pharmacy is expected to 
issue.  
 
In order to exercise this independent authority, pharmacists 
must first complete a course on “proper test administration 
and interpretation of results” from the CDC, and pharmacists 
must follow the recommendations for Mantoux TST. Idaho law 
requires pharmacists to maintain documentation of tests 
provided and provide a copy of the test results to the patient 
upon request. If a patient is found to have a positive TST 
reading, the pharmacist “shall coordinate a timely referral” to 
follow-up care. Further, the positive test results should be 
reported “in accordance with the rules governing Idaho 
reportable diseases.”  
 
Discussion 
Pharmacy-based TST holds potential for improving patient 
access, convenience, and affordability in a manner similar to 
pharmacy-based immunizations. Even after two decades of 
experience with immunizations, pharmacists still struggle with 
a patchwork of state laws allowing their prescribing and 
administration. While pharmacy-based immunizations are 
permissible in all 50 states, strategies include independent 
prescribing, statewide protocols, and CPAs and variation 
remains in the types of immunizations pharmacists may 
provide, and to the patient populations they may provide. 
 
The current legal environment for TST is much more limited 
than immunizations. We believe TST can be feasibly done in 
outpatient settings in at least 17 states under population-
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specific CPAs. In addition, two states have created 
autonomous pathways for TST. Table 2 reviews the core 
elements of the existing state laws that allow autonomous TST. 
Both New Mexico and Idaho provide similar structure, though 
Idaho defers more to clinical guidelines rather than reiterating 
these guidelines in law. For example, New Mexico delineates 
health screening requirements as part of the legal protocol 
whereas Idaho does not specifically list similar requirements in 
law. This does not absolve Idaho pharmacists from having to 
undertake a patient health screening; indeed, the clinical 
requirements require pharmacists to do so in order to properly 
evaluate the size of the induration when the patient returns in 
48 to 72 hours. Similarly, Idaho’s law is much less specific than 
the New Mexico protocol in terms of required pharmacist 
procedures. Idaho’s reference to the CDC guidelines covers the 
pharmacist procedures, and Idaho is spared from having to 
update their law every time clinical guidelines change. 
 
While CPAs will be the most common path forward for 
pharmacists looking to provide TST today, pharmacy 
stakeholders may consider pursuing more autonomous 
authority because it removes the burden of having to find a 
collaborating prescriber for a service that has already been 
established as safe and effective in pharmacies.15 Removing 
this “permission” step can lead to broader and more efficient 
uptake by pharmacists in all state, to the benefit of patients.16 
States looking to move TST to a more autonomous legal 
authority may consider approaches similar to Idaho and New 
Mexico when pursuing this authority. 
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Table 1: Tuberculin Purified Protein Derivative Products Available in the U.S. for Mantoux TST. 
 
Product Manufacturer NDCs 
Tubersol® Sanofi Pasteur Inc. 49281-752-78 (1mL) 
49281-752-98 (5mL) 
Aplisol® Par Pharmaceutical, Inc. 42023-104-01 (1mL) 
42023-104-05 (5mL) 
 
 
 
 
 
Table 2. Core Elements of Autonomous TST Prescribing Models 
 
Core Element New Mexico Protocol 
Requirements12-13 
Idaho Statutory Requirements14 
Pharmacist Education Requirement The pharmacist must successfully 
complete training as specified by 
the New Mexico department of 
health tuberculosis department and 
continuing education as specified by 
the CDC 
CDC online training 
Clinical Guidelines CDC guidelines CDC guidelines 
Health Screening Requirements Patient history, family history, 
current living environment, 
concurrent illness, allergies and 
hypersensitivities, medication 
history. 
Follow clinical guidelines 
Patient Education Requirements Skin test reaction drug information, 
lifestyle modifications, other 
information as appropriate 
Follow clinical guidelines 
Pharmacist Procedures Specific requirements are noted 
regarding the injection and the 
reading of the test. 
Follow clinical guidelines 
Notification to Primary Care 
Physician 
Within 15 days of writing any 
prescription 
Only for positive tests when 
coordinating a timely referral 
Notification to Department of 
Health 
Only for positive tests Only for active cases 
Recordkeeping Requirements Consent form, records of 
notification, billing, prescription 
order 
Documentation to be made 
available to patient upon request 
 
